FDA hits the brakes on His­to­gen's knee car­ti­lage ther­a­py, ask­ing for more in­fo on man­u­fac­tur­ing process

A month af­ter fil­ing the IND ap­pli­ca­tion for its hu­man ex­tra­cel­lu­lar ma­trix de­signed to re­gen­er­ate knee car­ti­lage, His­to­gen has hit a road­block.
The FDA on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER